Skip to main content
Top
Published in: Supportive Care in Cancer 5/2015

Open Access 01-05-2015 | Original Article

Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia

Authors: John M. Salsman, Jennifer L. Beaumont, Katy Wortman, Ying Yan, John Friend, David Cella

Published in: Supportive Care in Cancer | Issue 5/2015

Login to get access

Abstract

Purpose

Cancer anorexia-cachexia syndrome (CACS) is common in advanced cancer patients and associated with weight loss, fatigue, impaired quality of life (QoL), and poor prognosis. The goal of this project was to identify the most responsive items from two QoL measures in the ROMANA 2 (NCT01387282) phase III global study evaluating anamorelin HCl in the treatment of non-small cell lung cancer (NSCLC) cachexia: the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Functional Assessment of Anorexia/Cachexia Therapy (FAACT).

Methods

In the ROMANA 2 trial, 477 patients with unresectable stage III or IV NSCLC and cachexia were to be enrolled and randomized (2:1) to receive anamorelin HCl or placebo once daily for 12 weeks. All 203 patients who reached the week 12 visit at the time of data analysis were included. Co-primary endpoints were change from baseline in lean body mass and handgrip strength. QoL was a secondary outcome with FACIT-F and FAACT questionnaires administered at baseline and at weeks 3, 6, 9, and 12.

Results

Two 4-item scales (fatigue/activity and appetite/eating) from the FACIT-F and FAACT questionnaires, respectively, demonstrated good internal consistency reliability, validity, and responsiveness (also referred to as the Simplified Evaluation of Fatigue (SEF) and Simplified Evaluation of Appetite (SEA), respectively). The estimated important difference for each scale was 1–2 points.

Conclusions

These brief scales provide the psychometric properties necessary to promote future research in NSCLC patients with CACS. Additional work should examine the clinical utility of these scales and their impact on treatment decision-making.
Literature
1.
go back to reference Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495CrossRefPubMed Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495CrossRefPubMed
3.
go back to reference Johns N, Stephens NA, Fearon KCH (2013) Muscle wasting in cancer. Int J Biochem Cell Biol 45:2215–2229CrossRefPubMed Johns N, Stephens NA, Fearon KCH (2013) Muscle wasting in cancer. Int J Biochem Cell Biol 45:2215–2229CrossRefPubMed
4.
go back to reference World Health Organization (2013) Cancer - Fact sheet No. 297. In: Editor (ed)^(eds) Book Cancer - Fact sheet No. 297, City World Health Organization (2013) Cancer - Fact sheet No. 297. In: Editor (ed)^(eds) Book Cancer - Fact sheet No. 297, City
5.
go back to reference Davidoff AJ, Tang M, Seal B, Edelman MJ (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 28:2191–2197CrossRefPubMed Davidoff AJ, Tang M, Seal B, Edelman MJ (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 28:2191–2197CrossRefPubMed
6.
go back to reference Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O’Brien MER (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90:1905–1911CrossRefPubMedCentralPubMed Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O’Brien MER (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90:1905–1911CrossRefPubMedCentralPubMed
7.
go back to reference Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura LA (2012) Management of anorexia-cachexia in late-stage lung cancer patients. J Hosp Palliat Nurs 14:397–402CrossRef Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura LA (2012) Management of anorexia-cachexia in late-stage lung cancer patients. J Hosp Palliat Nurs 14:397–402CrossRef
8.
go back to reference Wallengren O, Lundholm K, Bosaeus I (2013) Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 21:1569–1577CrossRefPubMed Wallengren O, Lundholm K, Bosaeus I (2013) Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 21:1569–1577CrossRefPubMed
9.
go back to reference Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome Future Oncol: 1–14 Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome Future Oncol: 1–14
10.
go back to reference Garcia J, Boccia RV, Graham C, Kumor K, Polvino W (2007) A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol 18:9133 Garcia J, Boccia RV, Graham C, Kumor K, Polvino W (2007) A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol 18:9133
11.
go back to reference Garcia J, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21:129–137CrossRefPubMed Garcia J, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21:129–137CrossRefPubMed
12.
go back to reference Temel J, Bondarde S, Jain M, Allen S, Mann W (2013) Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter phase II study. European Cancer Congress. Amsterdam, The Netherlands,1308 In: Editor (ed)^(eds) Book Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter phase II study. European Cancer Congress. Amsterdam, The Netherlands,1308 City Temel J, Bondarde S, Jain M, Allen S, Mann W (2013) Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter phase II study. European Cancer Congress. Amsterdam, The Netherlands,1308 In: Editor (ed)^(eds) Book Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter phase II study. European Cancer Congress. Amsterdam, The Netherlands,1308 City
13.
go back to reference Temel J, Bondarde S, Jain M, Yan Y, Duus EM, Allen S, Mann W (2013) Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. 2013 ASCO’s Quality Care Symposium. In: Editor (ed)^(eds) Book Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. 2013 ASCO’s Quality Care Symposium, City Temel J, Bondarde S, Jain M, Yan Y, Duus EM, Allen S, Mann W (2013) Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. 2013 ASCO’s Quality Care Symposium. In: Editor (ed)^(eds) Book Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. 2013 ASCO’s Quality Care Symposium, City
14.
go back to reference Abernethy AP, Temel JS, Currow D (2013) Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia. In: Editor (ed)^(eds) Book Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia, City Abernethy AP, Temel JS, Currow D (2013) Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia. In: Editor (ed)^(eds) Book Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia, City
15.
go back to reference Grand S (1968) Color-word interference: an investigation of the role of vocal conflict and hunger in associative priming. J Exp Psychol 77:31–40CrossRefPubMed Grand S (1968) Color-word interference: an investigation of the role of vocal conflict and hunger in associative priming. J Exp Psychol 77:31–40CrossRefPubMed
16.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology 11:570–579 Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology 11:570–579
17.
go back to reference Smith E, Lai JS, Cella D (2010) Building a measure of fatigue: the functional assessment of chronic illness therapy fatigue scale. PM R 2:359–363CrossRefPubMed Smith E, Lai JS, Cella D (2010) Building a measure of fatigue: the functional assessment of chronic illness therapy fatigue scale. PM R 2:359–363CrossRefPubMed
18.
go back to reference Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137–1146CrossRefPubMed Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137–1146CrossRefPubMed
19.
go back to reference Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag 24:547–561CrossRef Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag 24:547–561CrossRef
20.
go back to reference Eton D, Cella D, Yount S, Peterman A, Neuberg D, Sledge GW, Wood W (2004) A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints ina breast cancer scale. J Clin Epidemiol 57:898–910CrossRefPubMed Eton D, Cella D, Yount S, Peterman A, Neuberg D, Sledge GW, Wood W (2004) A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints ina breast cancer scale. J Clin Epidemiol 57:898–910CrossRefPubMed
21.
go back to reference Yost KJ, Eton DT, Garcia SF, Cella D (2011) Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol 64:507–516CrossRefPubMedCentralPubMed Yost KJ, Eton DT, Garcia SF, Cella D (2011) Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol 64:507–516CrossRefPubMedCentralPubMed
22.
go back to reference Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag 13:63–74CrossRef Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag 13:63–74CrossRef
Metadata
Title
Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia
Authors
John M. Salsman
Jennifer L. Beaumont
Katy Wortman
Ying Yan
John Friend
David Cella
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2484-9

Other articles of this Issue 5/2015

Supportive Care in Cancer 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine